Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes. Its mortality rate accounts for 90% of all dermatologic tumor mortality. Traditional treatments such as surgery, chemotherapy, and radiotherapy are unable to achieve the expected r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/225 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588986671955968 |
|---|---|
| author | Xue Wang Shanshan Ma Shuting Zhu Liucun Zhu Wenna Guo |
| author_facet | Xue Wang Shanshan Ma Shuting Zhu Liucun Zhu Wenna Guo |
| author_sort | Xue Wang |
| collection | DOAJ |
| description | Malignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes. Its mortality rate accounts for 90% of all dermatologic tumor mortality. Traditional treatments such as surgery, chemotherapy, and radiotherapy are unable to achieve the expected results due to MM’s low sensitivity, high drug resistance, and toxic side effects. As treatment advances, immunotherapy and targeted therapy have made significant breakthroughs in the treatment of MM and have demonstrated promising application prospects. However, the heterogeneity of tumor immune response causes more than half of patients to not benefit from clinical immunotherapy and targeted therapy, which delays the patient’s condition and causes them to suffer adverse immune events’ side effects. The combination of immunotherapy and targeted therapy can help improve therapeutic effects, delay drug resistance, and mitigate adverse effects. This review provides a comprehensive overview of the current development status and research progress of immune checkpoints, targeted genes, and their inhibitors, with a view to providing a reference for the clinical treatment of MM. |
| format | Article |
| id | doaj-art-855de24400884390866d7c98d18dcd9c |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-855de24400884390866d7c98d18dcd9c2025-01-24T13:24:28ZengMDPI AGBiomedicines2227-90592025-01-0113122510.3390/biomedicines13010225Advances in Immunotherapy and Targeted Therapy of Malignant MelanomaXue Wang0Shanshan Ma1Shuting Zhu2Liucun Zhu3Wenna Guo4School of Life Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, ChinaSchool of Life Sciences, Shanghai University, Shanghai 200444, ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, ChinaMalignant melanoma (MM) is a malignant tumor, resulting from mutations in melanocytes of the skin and mucous membranes. Its mortality rate accounts for 90% of all dermatologic tumor mortality. Traditional treatments such as surgery, chemotherapy, and radiotherapy are unable to achieve the expected results due to MM’s low sensitivity, high drug resistance, and toxic side effects. As treatment advances, immunotherapy and targeted therapy have made significant breakthroughs in the treatment of MM and have demonstrated promising application prospects. However, the heterogeneity of tumor immune response causes more than half of patients to not benefit from clinical immunotherapy and targeted therapy, which delays the patient’s condition and causes them to suffer adverse immune events’ side effects. The combination of immunotherapy and targeted therapy can help improve therapeutic effects, delay drug resistance, and mitigate adverse effects. This review provides a comprehensive overview of the current development status and research progress of immune checkpoints, targeted genes, and their inhibitors, with a view to providing a reference for the clinical treatment of MM.https://www.mdpi.com/2227-9059/13/1/225malignant melanomaimmunotherapytargeted therapyinhibitorscombination therapyprecision medicine |
| spellingShingle | Xue Wang Shanshan Ma Shuting Zhu Liucun Zhu Wenna Guo Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma Biomedicines malignant melanoma immunotherapy targeted therapy inhibitors combination therapy precision medicine |
| title | Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma |
| title_full | Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma |
| title_fullStr | Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma |
| title_full_unstemmed | Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma |
| title_short | Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma |
| title_sort | advances in immunotherapy and targeted therapy of malignant melanoma |
| topic | malignant melanoma immunotherapy targeted therapy inhibitors combination therapy precision medicine |
| url | https://www.mdpi.com/2227-9059/13/1/225 |
| work_keys_str_mv | AT xuewang advancesinimmunotherapyandtargetedtherapyofmalignantmelanoma AT shanshanma advancesinimmunotherapyandtargetedtherapyofmalignantmelanoma AT shutingzhu advancesinimmunotherapyandtargetedtherapyofmalignantmelanoma AT liucunzhu advancesinimmunotherapyandtargetedtherapyofmalignantmelanoma AT wennaguo advancesinimmunotherapyandtargetedtherapyofmalignantmelanoma |